One of the hottest markets in the healthcare space is biotechnology companies looking to develop small molecule drugs to treat various forms of cancer. With billions of dollars being poured into cancer research each year, the companies involved in this space are attempting to create the next breakthrough therapy. One such company, Array BioPharma (ARRY), appears poised for greatness but it hasn't participated in the cancer rally over the past couple months which begs the question, why not? It appears the market has simply forgotten about Array while the major players continue to soar in value. Is this a problem or an opportunity? I believe it's a major opportunity.
Array BioPharma is a biopharmaceutical company focused...
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: